ArticleClinical rheumatology2019
Added value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome: lessons learned from year-long routine measurements.
Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Recurrent ischemic stroke with patent foramen ovale linked to seronegative antiphospholipid syndrome: a case report and literature review.Frontiers in immunology · 2025Review
- Beta-2 Glycoprotein I IgA Isotype: An Important Consideration in Secondary Hypertension.Cureus · 2024Article
- Non-criteria autoantibodies in antiphospholipid syndrome may be associated with underlying disease activity.Irish journal of medical science · 2024Article
- Current status and value of testing antiphospholipid antibody in patients with acute ischemic stroke: a retrospective single-center study in China.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Antiphospholipid Antibodies and Vascular Thrombosis in Patients with Severe Forms of COVID-19.Biomedicines · 2023Article
- Levels and avidities of antiphosphatidylethanolamine antibodies in patients with thrombotic events and immunologically-mediated diseases.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2023Article
- Criteria and Non-Criteria Antiphospholipid Antibodies in Antiphospholipid Syndrome: How Strong Are They Correlated?Biomedicines · 2023Article
- Thrombotic risk assessment in antiphospholipid syndrome: do noncriteria antibodies contribute?Turkish journal of medical sciences · 2023Article
- Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2.International journal of molecular sciences · 2022Article
- Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances.Journal of clinical medicine · 2022Review
- Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: Diagnostic value added.Frontiers in immunology · 2022Article
- Platelet distribution width is highly associated with thrombotic events in primary antiphospholipid syndrome.Clinical rheumatology · 2021Article
- Pulmonary manifestations of antiphospholipid syndrome: a retrospective analysis of 67 patients.Journal of thrombosis and thrombolysis · 2021Article
- The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis-A Two-Year Prospective Study.Biomedicines · 2021Article
- Article
- Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.Current neurology and neuroscience reports · 2021Review
- Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.Arthritis research & therapy · 2021Article
- Extracellular Vesicles and Antiphospholipid Syndrome: State-of-the-Art and Future Challenges.International journal of molecular sciences · 2021Review
- Comparison of Different Test Systems for the Detection of Antiphospholipid Antibodies in a Chinese Cohort.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The international classification criteria for definite antiphospholipid syndrome (APS) include three laboratory measurements: lupus anticoagulant (LA), IgG and IgM isotypes of anti-cardiolipin (aCL) and anti-β2glycoprotein I antibodies (anti-β2GPI). When persistently elevated, they are specific for APS; however, many patients that fulfil clinical criteria may exhibit negative serological results. These "seronegative" APS (SN-APS) are exposed to an increased thrombotic risk. The aims of our cross-sectional, retrospective study of consecutive autoimmune patients' samples were to evaluate the association of non-criteria antiphospholipid antibodies (aPL) with thrombosis and obstetric events, to calculate the risk score for adverse events and to assess the specific contribution of single aPL positivity in SN-APS. LA, aCL, anti-β2GPI and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) of IgG, IgM, and IgA isotypes were determined in sera of 323 patients with autoimmune disorders. Medical records of all patients were carefully analyzed. aCL, anti-β2GPI and aPS/PT of IgG and IgA isotypes were significantly associated with thrombosis while none of the IgM aPL showed such association. aPS/PT of all isotypes, aCL and anti-β2GPI of IgG and IgA isotype showed significant correlation to obstetric events. When considering results of aPS/PT ELISA, we could additionally identify 3% of thrombotic patients and 2% of obstetric patients. Thrombotic and obstetric risk scores were calculated showing significantly higher association to clinical events, as compared to evaluating individual risk factors. aPS/PT could represent an additional biomarker in SN-APS patients. IgA aPL are associated with thrombosis and obstetric complications. Risk scores accounting different aPL and conventional risk factors, better assesses risk for adverse event, as compared to evaluating individual factors alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.